Figure 7
Therapeutic effects of Hh101-infected carrier cells in an ovarian cancer model. Nude mice were engrafted intraperitoneally with SKOV3 cells and (a) treatment was started 3 days later using three repeated i.p. injections. Three repeated therapeutic injections of Hh101-infected human omentum mesothelial cells (HOmMCs) improved the survival of ovarian cancer-engrafted nude mice. Injections of Hh101-infected carrier cells were more effective than Hh101 injections alone. Some of the mice treated with Hh101-infected carrier cells survived without symptoms or site injection tumors for >80 days. (b) Therapy was started on day 6 with five repeated i.p. injections. Median survival was significantly (P=0.0018) prolonged for the group of carrier-cell-treated animals compared with the control group (median survival, 45 days vs 28 days).
